Sonnet BioTherapeutics (SONN) announced that the European Patent Office, EPO, has granted Patent No. EP3583125 B1, entitled “Albumin Binding Domain Fusion Proteins,” which covers Sonnet’s Fully Human Albumin Binding, FHAB, technology and includes therapeutic fusion proteins that utilize FHAB for tumor targeting and retention and provide extended pharmacokinetics, PK. The EU patent carries a term effective until February 20, 2038.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SONN:
- Sonnet BioTherapeutics files to sell 2M shares of common stock for holders
- Sonnet BioTherapeutics Expands Phase 1 Study for SON-1010
- Sonnet BioTherapeutics expands Phase 1 SB101 trial
- Sonnet BioTherapeutics reports FY24 EPS ($11.35) vs. ($145.13) last year
- Sonnet BioTherapeutics sees cash runway into July 2025